Incyte Corp. (INCY) Reports Positive Results from Phase IIa Trials of Topical JAK Inhibitor
Tweet Send to a Friend
Incyte Corporation (Nasdaq: INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
